Please note that eDoc will be permanently shut down in the first quarter of 2021!      Home News About Us Contact Contributors Disclaimer Privacy Policy Help FAQ

Quick Search
My eDoc
Session History
Support Wiki
Direct access to
document ID:

          Institute: MPI für Herz- und Lungenforschung (W. G. Kerckhoff Institut)     Collection: Yearbook_2015     Display Documents

ID: 711873.0, MPI für Herz- und Lungenforschung (W. G. Kerckhoff Institut) / Yearbook_2015
Novel and emerging therapies for pulmonary hypertension
Authors:Pullamsetti, S. S.; Schermuly, R.; Ghofrani, A.; Weissmann, N.; Grimminger, F.; Seeger, W.
Date of Publication (YYYY-MM-DD):2014-02-15
Title of Journal:Am J Respir Crit Care Med
Issue / Number:4
Start Page:394
End Page:400
Audience:Not Specified
Abstract / Description:The development of therapeutic concepts in pulmonary hypertension (PH) is intimately linked with the unraveling of pathogenetic sequelae. This perspective highlights advances in our understanding of the regulation of vasomotion and vascular remodeling that have led to "reverse-remodeling" and regenerative strategies as novel treatment concepts. Progress has been made in understanding redox-dependent signaling; inflammatory sequelae; and transcription factor, ion channel, and metabolic abnormalities, as well as growth factor-dependent hyperproliferation that underlies PH. We are, however, far from understanding the molecular pathways that differentially drive the various vascular phenotypes (intimal thickening, media hypertrophy, adventitial thickening, plexiform lesions, vascular pruning) in this disease. Antiproliferative strategies, transcription factor-based therapies, inflammation/immune cell-focused approaches, and epigenetic modulation-based therapies are all novel treatment concepts for PH. The proangiogenic potential of genetically engineered mesenchymal stem cells and endothelial progenitor cells has been explored as a regenerative strategy. The progress that has been made in identifying important cellular and molecular mechanisms and applying this knowledge to novel therapies is largely restricted to group 1 PH. However, understanding the molecular sequelae underlying PH in groups 2 through 5 PH is also urgently needed.
Free Keywords:Angiogenesis Inhibitors/therapeutic use; Antihypertensive Agents/*therapeutic use; Epigenesis, Genetic; Familial Primary Pulmonary Hypertension; Histone Deacetylase Inhibitors/therapeutic use; Humans; Hypertension, Pulmonary/*drug therapy/genetics/immunology/physiopathology; Protein Kinase Inhibitors/*therapeutic use; Pulmonary Artery/physiopathology; Pyrazoles/therapeutic use; Pyrimidines/therapeutic use; Sulfonamides/therapeutic use; Vasodilation; Vasodilator Agents/*therapeutic use
External Publication Status:published
Document Type:Article
Communicated by:MPI für Herz- und Lungenforschung
Affiliations:MPI für physiologische und klinische Forschung
External Affiliations:%^ 1435822045
Identifiers:ISSN:1535-4970 (Electronic) 1073-449X (Linking) %R 10.1164/rccm.201308-1543PP
The scope and number of records on eDoc is subject to the collection policies defined by each institute - see "info" button in the collection browse view.